
Sign up to save your podcasts
Or


In this episode of AbbottTalks, hosts Tom Salemi and Kayleen Brown sit down with Dr. Finn Gustafsson, Chief Medical Officer for Abbott’s Heart Failure business, to discuss how Abbott’s technologies are transforming care across every stage of heart failure.
Dr. Gustafsson—who spent decades in academic medicine before joining Abbott—explains how the company’s CentriMag™ System, HeartMate 3™ LVAD, and CardioMEMS™ HF System stabilize, sustain, and empower patients in each phase of the condition. The conversation explores what sets Abbott’s approach apart: early intervention through pulmonary artery pressure monitoring, mechanical circulatory support for critically ill patients, and long-term LVAD therapy that’s helping extend lives beyond five years. Lastly, Dr. Gustafsson shares insights from pivotal studies such as MOMENTUM 3, ARIES, and ASPIRE, which demonstrate how Abbott’s focus on evidence and patient experience is advancing the entire field.
This conversation comes to you courtesy of our episode sponsor, Tecan Group Ltd. To learn more about how Tecan works with medical device companies, visit: https://partnering.tecan.com/
Thank you for listening to the AbbottTalks podcast!
***
Enjoy this podcast? Follow AbbottTalks on all major podcast players: https://abbotttalks.castos.com/ Subscribe + Follow us on YouTube.com/@DeviceTalks to ensure you never miss an episode.
Want access to the complete DeviceTalks Podcast Network (DTPN)? Follow us today at https://devicetalks.castos.com/subscribe
By DeviceTalks Podcast Network4.7
4747 ratings
In this episode of AbbottTalks, hosts Tom Salemi and Kayleen Brown sit down with Dr. Finn Gustafsson, Chief Medical Officer for Abbott’s Heart Failure business, to discuss how Abbott’s technologies are transforming care across every stage of heart failure.
Dr. Gustafsson—who spent decades in academic medicine before joining Abbott—explains how the company’s CentriMag™ System, HeartMate 3™ LVAD, and CardioMEMS™ HF System stabilize, sustain, and empower patients in each phase of the condition. The conversation explores what sets Abbott’s approach apart: early intervention through pulmonary artery pressure monitoring, mechanical circulatory support for critically ill patients, and long-term LVAD therapy that’s helping extend lives beyond five years. Lastly, Dr. Gustafsson shares insights from pivotal studies such as MOMENTUM 3, ARIES, and ASPIRE, which demonstrate how Abbott’s focus on evidence and patient experience is advancing the entire field.
This conversation comes to you courtesy of our episode sponsor, Tecan Group Ltd. To learn more about how Tecan works with medical device companies, visit: https://partnering.tecan.com/
Thank you for listening to the AbbottTalks podcast!
***
Enjoy this podcast? Follow AbbottTalks on all major podcast players: https://abbotttalks.castos.com/ Subscribe + Follow us on YouTube.com/@DeviceTalks to ensure you never miss an episode.
Want access to the complete DeviceTalks Podcast Network (DTPN)? Follow us today at https://devicetalks.castos.com/subscribe

30,646 Listeners

8,754 Listeners

5,086 Listeners

3,218 Listeners

2,169 Listeners

1,836 Listeners

196 Listeners

1,448 Listeners

9,513 Listeners

9,194 Listeners

325 Listeners

350 Listeners

9,907 Listeners

668 Listeners

159 Listeners